Vericel Q2 revenue up 97% to $39.5M; raises FY2021 revenue guidance to $168-171M

Vericel Corp

2021-Q2 EPS reported -$0.15 revenue$74,087,000

Total net revenue $39.5M (+97% YoY); MACI $26.5M, Epicel $12.2M, NexoBrid $0.8M.
Net loss narrowed to $3.8M ($0.08/sh) from $8.3M loss; non-GAAP adjusted EBITDA $7.8M (20% margin).
Full-year 2021 revenue guidance raised to $168-171M; adjusted EBITDA margin guided to 23%-25%.
Record quarterly MACI biopsies and Epicel grafting; MACI biopsies up >50% in H1 2021 vs H1 2020.
Cash and investments $116M, no debt; operating cash flow $4.8M in Q2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.